Literature DB >> 16133232

[PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?].

M P Wirth1, F M Engelhardt.   

Abstract

PSA recurrence after primary curative therapy for localized prostate cancer is a common problem. Further curative treatment is only reasonable in the case of local recurrence. Therefore, minimizing the likelihood of metastatic disease is crucial. So far, imaging techniques cannot distinguish between local recurrence and distant metastasis. It is therefore reasonable to orientate on PSA kinetics and pathological criteria. Histologic confirmation of suspected local recurrence after radical prostatectomy before salvage therapy is not required. However, after initial radiation therapy histologic confirmation of suspected isolated local recurrence should be obtained. The optimal treatment for a PSA recurrence depends on the initial therapy and the life-expectancy of the patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133232     DOI: 10.1007/s00120-005-0879-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  73 in total

1.  Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.

Authors:  C I Sartor; M H Strawderman; X H Lin; K E Kish; P W McLaughlin; H M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-15       Impact factor: 7.038

2.  Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.

Authors:  C Hofer; C Laubenbacher; T Block; J Breul; R Hartung; M Schwaiger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

3.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.

Authors:  T R DeGrado; R E Coleman; S Wang; S W Baldwin; M D Orr; C N Robertson; T J Polascik; D T Price
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

4.  Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.

Authors:  W R Lee; G E Hanks; A Hanlon
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

5.  Value of endorectal coil versus body coil MRI for diagnosis of recurrent pelvic malignancies.

Authors:  R A Huch Böni; C Meyenberger; J Pok Lundquist; F Trinkler; U Lütolf; G P Krestin
Journal:  Abdom Imaging       Date:  1996 Jul-Aug

6.  Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography.

Authors:  Albert Gelet; Jean Yves Chapelon; Laura Poissonnier; Raymonde Bouvier; Olivier Rouvière; Laura Curiel; Marc Janier; Guy Vallancien
Journal:  Urology       Date:  2004-04       Impact factor: 2.649

7.  Salvage brachytherapy for localized prostate cancer after radiotherapy failure.

Authors:  G L Grado; J M Collins; J S Kriegshauser; C S Balch; M M Grado; G P Swanson; T R Larson; M M Wilkes; R J Navickis
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

8.  A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria.

Authors:  Matthew B Gretzer; Bruce J Trock; Misop Han; Patrick C Walsh
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

9.  Follow-up surveillance strategies for genitourinary malignancies.

Authors:  Christopher P Evans
Journal:  Cancer       Date:  2002-06-01       Impact factor: 6.860

10.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.

Authors:  A W Partin; J D Pearson; P K Landis; H B Carter; C R Pound; J Q Clemens; J I Epstein; P C Walsh
Journal:  Urology       Date:  1994-05       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.